SOUTH SAN FRANCISCO, Calif. - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm focused on allogeneic CAR T therapies, has entered into a licensing agreement with Arbor Biotechnologies for the use of Arbor's CRISPR gene-editing technology. This collaboration aims to advance the development of treatments for autoimmune diseases using Allogene's AlloCAR T™ platform.
The partnership, announced today, grants Allogene access to Arbor's proprietary gene-editing tools, which the company plans to utilize in creating new allogeneic CAR T therapies. These investigational products are designed to be more effective and widely accessible for autoimmune disease treatment, with the first Phase 1 clinical trial expected to commence in early 2025.
Allogene's Executive Vice President of Research & Development and Chief Medical Officer, Zachary Roberts, M.D., Ph.D., expressed the scientific community's keen interest in CAR T's potential for autoimmune diseases and stressed the importance of differentiation in the crowded field.
Allogene's approach includes designing investigational products that may allow reduced or even chemotherapy-free conditioning, fitting the scale of the autoimmune disease market and the needs of patients.
Arbor's CEO, Devyn Smith, Ph.D., echoed the sentiment, highlighting the potential of gene editing to transform treatment paradigms and improve patient outcomes. Arbor's technology suite, developed through a combination of CRISPR, computational AI-driven discovery, and protein engineering, positions the company as a next-generation gene editing enterprise.
Allogene, headquartered in South San Francisco, is pioneering off-the-shelf CAR T cell products for cancer and autoimmune diseases. Arbor, based in Cambridge, Mass., focuses on a range of genetic medicines, with an emphasis on liver-mediated and CNS diseases. Both companies have emphasized the importance of strategic partnerships in advancing their respective technologies and therapies.
This news is based on a press release statement and contains forward-looking statements regarding the development and potential benefits of AlloCAR T products, as well as the anticipated timing of clinical trials. These statements are subject to various risks and uncertainties, and actual results may differ materially. Allogene's SEC filings, including its most recent 10-Q report, provide a detailed discussion of these risks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.